VolitionRx, Avalo Therapeutic among healthcare movers
Seeking Alpha News (Fri, 22-Sep 9:59 AM ET)
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Globe Newswire (Tue, 5-Sep 8:05 AM ET)
ACCESSWIRE (Thu, 17-Aug 9:02 AM ET)
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 9-Aug 8:05 AM ET)
Globe Newswire (Wed, 26-Jul 8:30 AM ET)
ACCESSWIRE (Wed, 19-Jul 9:00 AM ET)
ACCESSWIRE (Tue, 18-Jul 9:02 AM ET)
ACCESSWIRE (Tue, 11-Jul 9:15 AM ET)
ACCESSWIRE (Wed, 5-Jul 9:01 AM ET)
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Agile Therapeutics trades on the NASDAQ stock market under the symbol AGRX.
As of September 25, 2023, AGRX stock price climbed to $1.80 with 28,782 million shares trading.
AGRX has a beta of 1.12, meaning it tends to be more sensitive to market movements. AGRX has a correlation of 0.05 to the broad based SPY ETF.
AGRX has a market cap of $3.47 million. This is considered a Sub-Micro Cap stock.
Last quarter Agile Therapeutics reported $6 million in Revenue and -$3.10 earnings per share. This beat revenue expectation by $823,000 and exceeded earnings estimates by $.38.
In the last 3 years, AGRX stock traded as high as $7,540.00 and as low as $1.65.
The top ETF exchange traded funds that AGRX belongs to (by Net Assets): VXF, ITOT.
AGRX has underperformed the market in the last year with a price return of -88.1% while the SPY ETF gained +17.2%. AGRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -37.3% and -14.3%, respectively, while the SPY returned -0.6% and -2.6%, respectively.
AGRX support price is $1.64 and resistance is $1.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGRX stock will trade within this expected range on the day.